|
US7238673B2
(en)
|
1989-03-31 |
2007-07-03 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
US7745416B2
(en)
*
|
1995-04-11 |
2010-06-29 |
The Regents Of The University Of California |
Method for in vivo regulation of cardiac muscle contractility
|
|
JP4002605B2
(ja)
*
|
1995-06-07 |
2007-11-07 |
ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
筋組織のａａｖ形質導入
|
|
US20010009904A1
(en)
*
|
1997-12-30 |
2001-07-26 |
Jon A. Wolff |
Process of delivering a polynucleotide to a cell via the vascular system
|
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
|
US5962313A
(en)
*
|
1996-01-18 |
1999-10-05 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
|
|
US5858351A
(en)
*
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
|
US5846528A
(en)
*
|
1996-01-18 |
1998-12-08 |
Avigen, Inc. |
Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
|
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
|
US20020037867A1
(en)
*
|
1999-02-26 |
2002-03-28 |
James M. Wilson |
Method for recombinant adeno-associated virus-directed gene therapy
|
|
IL128779A0
(en)
*
|
1996-09-06 |
2000-01-31 |
Univ Pennsylvania |
Method for recombinant adeno-associated virus-directed gene therapy
|
|
US6242426B1
(en)
*
|
1997-07-25 |
2001-06-05 |
Avigen, Inc. |
Induction of immune response to antigens expressed by recombinant adeno-associated virus
|
|
AU8672198A
(en)
*
|
1997-07-31 |
1999-02-22 |
Chiron Corporation |
Method enabling readministration of aav vector via immunosuppression of host
|
|
US6989264B2
(en)
*
|
1997-09-05 |
2006-01-24 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
|
US6346415B1
(en)
*
|
1997-10-21 |
2002-02-12 |
Targeted Genetics Corporation |
Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
|
|
ES2268799T3
(es)
*
|
1997-10-29 |
2007-03-16 |
Genzyme Corporation |
Terapia genica para la enfermedad de gaucher.
|
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
|
US6491907B1
(en)
*
|
1998-11-10 |
2002-12-10 |
The University Of North Carolina At Chapel Hill |
Recombinant parvovirus vectors and method of making
|
|
US6303362B1
(en)
*
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
|
AU1557000A
(en)
*
|
1998-11-20 |
2000-06-13 |
Autonomous University of Barcelona, The |
Insulin production by engineered muscle cells
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6509150B1
(en)
*
|
1999-03-05 |
2003-01-21 |
Universite De Nantes |
Compositions and methods for recombinant Adeno-Associated Virus production
|
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
|
AU1775901A
(en)
*
|
1999-11-17 |
2001-05-30 |
Avigen, Inc. |
Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
|
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
|
AU2002258747A1
(en)
*
|
2001-04-09 |
2002-10-21 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Synthesis and secretion of recombinant lysosomal enzymes by liver
|
|
WO2003013570A1
(fr)
*
|
2001-08-09 |
2003-02-20 |
Cornell Research Foundation, Inc. |
Protection du facteur de croissance derive de plaquettes du myocarde
|
|
CA2460157A1
(fr)
|
2001-09-18 |
2003-03-27 |
Clontech Laboratories, Inc. |
Procede de producteur dde vecteurs adenoviraux s'appuyant sur une recombinase specifique d'un site
|
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
|
AU2003223497A1
(en)
*
|
2002-04-05 |
2003-10-27 |
Centocor, Inc. |
Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
|
|
AU2003223780A1
(en)
*
|
2002-04-30 |
2003-11-17 |
University Of Florida |
Treatment for pompe disease
|
|
AU2003223775A1
(en)
*
|
2002-04-30 |
2003-11-17 |
Duke University |
Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
|
|
JP2005536231A
(ja)
*
|
2002-05-08 |
2005-12-02 |
イントロン，インコーポレーテッド |
アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
|
|
WO2004038380A2
(fr)
*
|
2002-10-23 |
2004-05-06 |
Intronn, Inc. |
Procedes de criblage destines a identifier des molecules de pre-trans-epissage efficaces
|
|
US7803365B2
(en)
*
|
2002-12-02 |
2010-09-28 |
Biovec, Llc |
Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
|
|
US9388427B2
(en)
|
2002-12-02 |
2016-07-12 |
Biovec, Llc |
In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
|
|
US20040248262A1
(en)
*
|
2003-01-22 |
2004-12-09 |
Koeberl Dwight D. |
Constructs for expressing lysomal polypeptides
|
|
WO2004076635A2
(fr)
*
|
2003-02-25 |
2004-09-10 |
Biovec B.V. |
Applications therapeutiques du gene de la thrombomoduline au moyen de vecteurs viraux et non viraux
|
|
US7056674B2
(en)
|
2003-06-24 |
2006-06-06 |
Genomic Health, Inc. |
Prediction of likelihood of cancer recurrence
|
|
US8007778B2
(en)
*
|
2003-07-01 |
2011-08-30 |
The Regents Of The University Of California |
Use of calcium binding proteins to improve cardiac contractile function
|
|
JP2007510753A
(ja)
*
|
2003-11-12 |
2007-04-26 |
アミカス セラピューティックス インコーポレイテッド |
ゴーシェ病を治療するための、グルコイミダゾール誘導体およびポリヒドロキシシクロヘキセニルアミン誘導体
|
|
US7129049B2
(en)
*
|
2003-12-22 |
2006-10-31 |
Regents Of The University Of Minnesota |
Method of detecting equine glycogen storage disease IV
|
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
|
AU2005207053A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Virxsys Corporation |
Expression of ApoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
|
|
WO2005070948A1
(fr)
*
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Correction de defauts genetiques lies a l'alpha-1-antitrypsine par transepissage d'arn a mediation par spliceosome
|
|
US20060078542A1
(en)
*
|
2004-02-10 |
2006-04-13 |
Mah Cathryn S |
Gel-based delivery of recombinant adeno-associated virus vectors
|
|
WO2005116224A2
(fr)
*
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Vecteurs viraux adeno-associes regules par la tetracycline pour l'administration de gene au systeme nerveux
|
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
|
AU2005326784B2
(en)
*
|
2004-10-08 |
2012-03-15 |
Virxsys Corporation |
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
|
US7892809B2
(en)
*
|
2004-12-15 |
2011-02-22 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
|
JP5623740B2
(ja)
*
|
2006-07-25 |
2014-11-12 |
セラドン・コーポレーション |
遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
|
|
US20100221225A1
(en)
*
|
2007-02-23 |
2010-09-02 |
University Of Florida Research Foundation, Inc |
Compositions and methods for treating glycogen storage diseases
|
|
US20120322861A1
(en)
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
EP2244740A1
(fr)
|
2008-02-19 |
2010-11-03 |
Celladon Corporation |
Compositions pour un captage amélioré de vecteurs viraux dans le myocarde
|
|
WO2009155936A1
(fr)
|
2008-06-26 |
2009-12-30 |
Orphazyme Aps |
Utilisation du hsp70 en tant que régulateur de l'activité enzymatique
|
|
US8889641B2
(en)
|
2009-02-11 |
2014-11-18 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
BR112013013143A2
(pt)
|
2010-11-30 |
2016-08-23 |
Orphazyme Aps |
composto, e, método de tratamento de uma doença de armazenagem lisossômica
|
|
WO2013066438A2
(fr)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Évaluation et amélioration de la spécificité de clivage des nucléases
|
|
AU2013277215A1
(en)
|
2012-06-19 |
2015-02-05 |
University Of Florida Research Foundation, Inc. |
Compositions and methods for treating diseases
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
US9068179B1
(en)
|
2013-12-12 |
2015-06-30 |
President And Fellows Of Harvard College |
Methods for correcting presenilin point mutations
|
|
EP3909602A1
(fr)
|
2014-04-25 |
2021-11-17 |
University of Florida Research Foundation, Inc. |
Méthodes permettant qu'un sujet reçoive des doses multiples de virus adéno-associé recombinant
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
CA2956224A1
(fr)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Proteines cas9 comprenant des inteines dependant de ligands
|
|
HUE054957T2
(hu)
|
2014-09-15 |
2021-10-28 |
Orphazyme As |
Arimoklomol készítése
|
|
EP3215191B1
(fr)
|
2014-11-05 |
2024-08-14 |
Voyager Therapeutics, Inc. |
Polynucléotides codant pour la dopa décarboxylase et destinés au traitement de la maladie de parkinson
|
|
RU2716422C2
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
CN112410339A
(zh)
|
2014-11-14 |
2021-02-26 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
US10900053B2
(en)
|
2014-11-21 |
2021-01-26 |
University Of Florida Research Foundation, Incorporated |
Genome-modified recombinant adeno-associated virus vectors
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
AU2016256895B2
(en)
|
2015-05-07 |
2022-05-26 |
Takeda Pharmaceutical Company Limited |
Glucocerebrosidase gene therapy for parkinson's disease
|
|
JP7067793B2
(ja)
|
2015-10-23 |
2022-05-16 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
核酸塩基編集因子およびその使用
|
|
US10983110B2
(en)
|
2015-12-02 |
2021-04-20 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
EP3442530A1
(fr)
|
2016-04-13 |
2019-02-20 |
Orphazyme A/S |
Protéines de choc thermique et homéostasie du cholestérol
|
|
KR102598289B1
(ko)
|
2016-04-16 |
2023-11-06 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
바큘로바이러스 시스템-생산된 재조합 아데노-연관 바이러스의 생물학적 효력을 증진시키는 방법
|
|
WO2017189959A1
(fr)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions pour le traitement de maladies
|
|
DK3448382T3
(da)
|
2016-04-29 |
2020-12-07 |
Orphazyme As |
Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
|
|
WO2017189964A2
(fr)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions pour le traitement de maladies
|
|
RU2758488C2
(ru)
|
2016-05-18 |
2021-10-28 |
Вояджер Терапьютикс, Инк. |
Модулирующие полинуклеотиды
|
|
RU2764587C2
(ru)
|
2016-05-18 |
2022-01-18 |
Вояджер Терапьютикс, Инк. |
Способы и композиции для лечения хореи гентингтона
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
CA3033327A1
(fr)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Proteines de fusion cas9-recombinase programmables et utilisations associees
|
|
WO2018039438A1
(fr)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
|
|
CN110650673B
(zh)
|
2016-08-30 |
2024-04-09 |
加利福尼亚大学董事会 |
用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
|
|
US11306324B2
(en)
|
2016-10-14 |
2022-04-19 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
|
CA3114549A1
(fr)
|
2017-02-21 |
2018-08-30 |
University Of Florida Research Foundation, Incorporated |
Proteines des capsides aav modifiees et leurs utilisations
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
CA3057192A1
(fr)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Editeurs de nucleobase comprenant des proteines de liaison a l'adn programmable par acides nucleiques
|
|
CA3061652A1
(fr)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions et methodes de traitement de la sclerose laterale amyotrophique (sla)
|
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
WO2018209320A1
(fr)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
|
|
KR102760654B1
(ko)
|
2017-06-07 |
2025-02-04 |
리제너론 파마슈티칼스 인코포레이티드 |
효소 내재화를 위한 조성물 및 방법
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
WO2019018342A1
(fr)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Systeme de guide de trajectoire d'appareillage en reseau
|
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
|
EP3808849A1
(fr)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Compositions et procédés pour l'administration d'aav
|
|
WO2019139645A2
(fr)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
Éditeurs de bases à haut rendement comprenant une gam
|
|
US20200263199A1
(en)
|
2017-09-29 |
2020-08-20 |
Voyager Therapeutics, Inc. |
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
|
|
TWI804518B
(zh)
|
2017-10-16 |
2023-06-11 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
AU2018352592B2
(en)
|
2017-10-16 |
2025-03-27 |
Beam Therapeutics, Inc. |
Uses of adenosine base editors
|
|
EP4454654A3
(fr)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Traitement de la sclérose latérale amyotrophique (sla)
|
|
CA3090519A1
(fr)
|
2018-02-07 |
2019-08-15 |
Regeneron Pharmaceuticals, Inc. |
Procedes et compositions pour l'administration de proteines therapeutiques
|
|
CA3092107A1
(fr)
|
2018-02-28 |
2019-09-06 |
The University Of North Carolina At Chapel Hill |
Methodes et compositions pour vecteurs viraux evitant les anticorps
|
|
CA3095179A1
(fr)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Vecteurs viraux evitant les anticorps
|
|
US12116384B2
(en)
|
2018-04-03 |
2024-10-15 |
Ginkgo Bioworks, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
MX2020010464A
(es)
|
2018-04-03 |
2021-01-29 |
|
Vectores de virus que evitan anticuerpos.
|
|
AU2019269685A1
(en)
|
2018-05-17 |
2020-12-03 |
Regeneron Pharmaceuticals, Inc. |
Anti-CD63 antibodies, conjugates, and uses thereof
|
|
WO2019226953A1
(fr)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Éditeurs de bases et leurs utilisations
|
|
JP2021526818A
(ja)
|
2018-06-08 |
2021-10-11 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
心筋症のためのａａｖ心臓遺伝子治療
|
|
EP3810782A2
(fr)
|
2018-06-22 |
2021-04-28 |
Asklepios Biopharmaceutical, Inc. |
Vecteurs pour l'administration de gènes qui persistent dans les cellules
|
|
CN113383010A
(zh)
|
2018-09-28 |
2021-09-10 |
沃雅戈治疗公司 |
具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
JP7669281B2
(ja)
|
2019-03-19 |
2025-04-28 |
ザ ブロード インスティテュート，インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
|
TW202102525A
(zh)
|
2019-03-21 |
2021-01-16 |
美商史崔德生物公司 |
重組腺相關病毒載體
|
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
|
US20220249697A1
(en)
|
2019-05-20 |
2022-08-11 |
The Broad Institute, Inc. |
Aav delivery of nucleobase editors
|
|
US20240417715A1
(en)
|
2019-10-10 |
2024-12-19 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
|
MX2022004352A
(es)
|
2019-10-17 |
2022-07-19 |
Stridebio Inc |
Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c.
|
|
CN116096873A
(zh)
|
2020-05-08 |
2023-05-09 |
布罗德研究所股份有限公司 |
同时编辑靶标双链核苷酸序列的两条链的方法和组合物
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
JP2023536091A
(ja)
|
2020-07-27 |
2023-08-23 |
ボイジャー セラピューティクス インコーポレイテッド |
グルコシルセラミダーゼベータ欠損に関連する神経障害の治療のための組成物及び方法
|
|
MX2023002016A
(es)
|
2020-08-19 |
2023-06-26 |
Sarepta Therapeutics Inc |
Vectores de virus adenoasociados para el tratamiento del sindrome de rett.
|
|
WO2022106614A1
(fr)
|
2020-11-19 |
2022-05-27 |
Orphazyme A/S |
Procédés de préparation de citrate d'arimoclomol et intermédiaires associés
|
|
JP2024501957A
(ja)
|
2020-12-23 |
2024-01-17 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
心臓遺伝子治療のためのベクターの増大したパッケージング効率
|
|
US20240417719A1
(en)
|
2021-10-25 |
2024-12-19 |
The Broad Institute, Inc. |
Methods and compositions for editing a genome with prime editing and a recombinase
|
|
EP4433490A2
(fr)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Compositions et méthodes de traitement de troubles neurologiques liés à un déficit en bêta glucosylcéramidase
|
|
EP4504925A1
(fr)
|
2022-04-04 |
2025-02-12 |
The Broad Institute, Inc. |
Variantes de cas9 ayant des spécificités pam non canoniques et leurs utilisations
|
|
AU2023259642A1
(en)
|
2022-04-28 |
2024-11-14 |
President And Fellows Of Harvard College |
Aav vectors encoding base editors and uses thereof
|
|
WO2023240236A1
(fr)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale
|
|
WO2024040083A1
(fr)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Cytosine désaminases évoluées et méthodes d'édition d'adn l'utilisant
|
|
WO2024108092A1
(fr)
|
2022-11-17 |
2024-05-23 |
The Broad Institute, Inc. |
Distribution d'éditeur primaire par vaa
|
|
WO2024163012A1
(fr)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions et méthodes de traitement de troubles neurologiques liés à un déficit en bêta glucosylcéramidase
|
|
WO2025090858A1
(fr)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Procédés d'identification de variants de capside de vaa ayant des caractéristiques souhaitées
|